BioTuesdays

Tag - William Plovanic

Acutes-Medical-Logo

Canaccord cuts Acutus Medical to hold; PT to $3

Canaccord Genuity downgraded Acutus Medical (NASDAQ:AFIB) to “hold” from “buy” and slashed its price target to $3 from $10, citing a financing/dilution risk. The stock closed at $3.02 on Jan. 13. Acutus is an arrhythmia...

Acutes-Medical-Logo

Analysts cut Acutus Medical PT to $8 and $10

Analysts for BTIG and Canaccord Genuity reduced their price targets for Acutus Medical (NASDAQ:AFIB) to $8 from $20 and to $10 from $18, respectively, but maintain their “buy” ratings, after the company reported third...

CVRx

Canaccord starts CVRx at buy; PT $30

Canaccord Genuity initiated coverage of CVRx (NASDAQ:CVRX) with a “buy” rating and price target of $30. The stock closed at $20.22 on July 23. “We believe that CVRx is uniquely positioned in addressing significant unmet...

TransMedics logo

Canaccord ups TransMedics PT to $79 from $46

Canaccord Genuity raised its price target for TransMedics Group (NASDAQ:TMDX) to $79 from $46, saying the company has the “technology that will become the standard of care for organ transplant and in the process...

TransMedics logo

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

Neuronetics Logo

Canaccord ups Neuronetics PT to $20 from $8

Canaccord Genuity raised its price target for Neuronetics (NASDAQ:STIM) to $20 from $8, reflecting the company’s strong fourth quarter preliminary financial results and a new focus on high-margin utilization, compared...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.